A nitric oxide-donor pravastatin hybrid drug exerts antiplatelet and antiatherogenic activity in mice
Bleeding, Thrombosis and Vascular Biology · 2022
DOI: 10.4081/btvb.2022.19 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bleeding, Thrombosis and Vascular Biology, 2022. Verfasst von Stefania Momi und 5 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aim of the present study was to compare the lipid-lowering, antithrombotic and antiatherogenic properties of NCX-6550, nitropravastatin, a nitric-oxide donating derivative of pravastatin, with those of pravastatin in hypercholesterolemic mice. LDL receptor-deficient mice (LDLR–/–) on a normal diet (ND) showed enhanced cholesterol levels as compared to wild type (WT) mice (6.8±1.2 mmol/L and 2.8±0.82 mmol/L, respectively). High fat diet (HFD) induced a large enhancement of cholesterolemia in LDLR–/– mice (23.7±5.7 mmol/L, p
Zitieren
APA
Momi, S., Guglielmini, G., Taranta, G. C., Giglio, E., Monopoli, A., & Gresele, P. (2022). A nitric oxide-donor pravastatin hybrid drug exerts antiplatelet and antiatherogenic activity in mice. Bleeding, Thrombosis and Vascular Biology. https://doi.org/10.4081/btvb.2022.19
Vancouver
Momi S, Guglielmini G, Taranta GC, Giglio E, Monopoli A, Gresele P. A nitric oxide-donor pravastatin hybrid drug exerts antiplatelet and antiatherogenic activity in mice. Bleeding, Thrombosis and Vascular Biology. 2022. doi:10.4081/btvb.2022.19
BibTeX
@article{Momi2022,
author = {Momi, Stefania and Guglielmini, Giuseppe and Taranta, Giulia Ciarroca and Giglio, Elisa and Monopoli, Angela and Gresele, Paolo},
title = {A nitric oxide-donor pravastatin hybrid drug exerts antiplatelet and antiatherogenic activity in mice},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2022},
doi = {10.4081/btvb.2022.19}
}
EUVIMED